• Line Dam Heftdal, Andreas Dehlbaek Knudsen, Sebastian Rask Hamm, Cecilie Bo Hansen, Dina Leth Møller, Mia Pries-Heje, Kamille Fogh, Rasmus Bo Hasselbalch, Ida Jarlhelt, Laura Pérez-Alós, Linda Maria Hilsted, Sisse Rye Ostrowski, Jan Gerstoft, Kirsten Grønbaek, Henning Bundgaard, Kasper Iversen, Peter Garred, and Susanne Dam Nielsen.
• Viro-Immunology Research Unit, Department of Infectious Diseases, Section 8632, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
• J. Intern. Med. 2022 Apr 1; 291 (4): 513-518.

BackgroundPeople with HIV (PWH) are at increased risk of severe COVID-19. We aimed to determine humoral responses in PWH and controls who received two doses of BNT162b2.MethodsIn 269 PWH and 538 age-matched controls, we measured IgG and neutralizing antibodies specific for the receptor-binding domain of SARS-CoV-2 at baseline, 3 weeks and 2 months after the first dose of BNT162b2.ResultsIgG antibodies increased from baseline to 3 weeks and from 3 weeks to 2 months in both groups, but the concentrations of IgG antibodies were lower in PWH than that in controls at 3 weeks and 2 months (p = 0.025 and <0.001), respectively. The IgG titres in PWH with a humoral response at 2 months were 77.9% (95% confidence interval [62.5%-97.0%], age- and sex-adjusted p = 0.027) of controls.ConclusionsReduced IgG antibody response to vaccination with BNT162b2 was found in PWH, and thus increased awareness of breakthrough infections in PWH is needed.© 2021 The Association for the Publication of the Journal of Internal Medicine.

15 keywords...

hide…